Federal Register / Vol. 82, No. 195 / Wednesday, October 11, 2017 / Notices 47291 

existing interchanges and adding 

capacity along the corridor. 

WisDOT has notified FHWA that 

pursuant to s. 84.0145, Wis. Stats., the 

Legislature must specifically authorize 

WisDOT to proceed with the project. 

The recently approved 2017 Wisconsin 

Act 59, the State’s biennial budget, did 

not authorize WisDOT to advance the 

project. Therefore, FHWA has 

determined, in conjunction with 

WisDOT, that the ROD shall be 

rescinded. Any future environmental 

action within this corridor will comply 

with environmental review 

requirements of the National 

Environmental Policy Act ((NEPA) (42 

U.S.C. 4321, et seq.)), FHWA 

environmental regulations (23 CFR 771), 

and related authorities prior to 

reissuance of a ROD or other NEPA 

documentation, as appropriate. 

Comments and questions concerning 

this action should be directed to FHWA 

at the address provided above. 

(Catalog of Federal Domestic Assistance 

Program Number 20.205, Highway Planning 

and Construction. The regulations 

implementing Executive Order 12372 

regarding intergovernmental consultation on 

Federal programs and activities apply to this 

program.) 

Issued on: October 4, 2017. 

Timothy C. Marshall, 

Assistant Division Administrator, FHWA 

Wisconsin Division, Madison, Wisconsin. 

[FR Doc. 2017–21917 Filed 10–10–17; 8:45 am] 

BILLING CODE 4910–22–P 

DEPARTMENT OF TRANSPORTATION 

Federal Highway Administration 

Tier 1 Environmental Impact Statement 

for the Chesapeake Bay Crossing 

Study, Anne Arundel County, 

Baltimore County, Calvert County, 

Cecil County, Dorchester County, 

Harford County, Kent County, Queen 

Anne’s County, St. Mary’s County, 

Somerset County, and Talbot County, 

Maryland 

AGENCY: Federal Highway 

Administration (FHWA), Maryland 

Transportation Authority (MDTA), DOT. 

ACTION: Notice of intent to prepare a 

Tier 1 Environmental Impact Statement 

(EIS). 

SUMMARY: The FHWA, as the Lead 

Federal Agency, and MDTA, as the 

Local Project Sponsor, are issuing this 

notice to advise the public of our 

intention to prepare a Tier 1 EIS for the 

Chesapeake Bay Crossing Study in 

Maryland. The Tier 1 EIS will assess the 

potential environmental impacts of 

addressing congestion at the Chesapeake 

Bay Bridge, which could result in added 

capacity at the existing bridge or at a 

new location across the Chesapeake 

Bay. The Tier 1 EIS will be prepared in 

accordance with regulations 

implementing the National 

Environmental Policy Act (NEPA) and 

provisions of the Fixing America’s 

Surface Transportation Act (FAST Act) 

and will include a range of reasonable 

corridor alternatives, including a ‘‘No 

Build’’ alternative. 

FOR FURTHER INFORMATION CONTACT: 

Jeanette Mar, Environmental Program 

Manager, Federal Highway 

Administration, Maryland Division, 10 

S. Howard Street, Suite 2450, Baltimore, 

MD 21201, (410) 779–7152, or email at 

jeanette.mar@dot.gov. Melissa Williams, 

Director, Division of Planning & 

Program Development, Maryland 

Transportation Authority, 2310 

Broening Highway, Baltimore, MD 

21224, (410) 537–5650, or email at 

mwilliams9@mdta.state.md.us. 

SUPPLEMENTARY INFORMATION: The 

purpose of this notice is to: (1) Alert 

interested parties to the FHWA and 

MDTA plan to prepare the Tier 1 EIS; 

(2) provide information on the nature of 

the proposed action; (3) solicit public 

and agency input regarding the scope of 

the Tier 1 EIS, including the purpose 

and need, alternatives to be considered, 

and impacts to be evaluated; and (4) 

announce that public and agency 

scoping meetings will be conducted. 

The Chesapeake Bay Crossing Study 

Tier 1 EIS will identify the preferred 

corridor alternative for addressing 

congestion at the Chesapeake Bay 

Bridge and evaluate its financial 

viability. The study area is a broad 

geographic area that includes the entire 

length of the Chesapeake Bay in 

Maryland, spanning approximately 100 

miles from the northern end near Havre 

de Grace to the southern border with 

Virginia between St. Mary’s and 

Somerset Counties. The study will 

include a review of existing roadway 

infrastructure and environmental 

conditions along both shores of the Bay 

to identify potential crossing corridors 

in Maryland. Each potential corridor 

alternative will consist of a corridor 

band approximately one mile wide. This 

width may be adjusted to accommodate 

the specific conditions at each crossing 

as the study progresses. 

Once the full range of potential 

corridor alternatives is developed, the 

study will include identification of a 

range of reasonable corridor alternatives 

for screening. It is assumed that 

approximately ten to fifteen corridors 

will be identified as reasonable for 

additional study. These corridors will 

then be screened based on measurable 

criteria to the corridor alternatives that 

will be retained for analysis in the Tier 

1 Draft EIS. The EIS will be prepared by 

MDTA for FHWA to fulfill the 

requirements established in NEPA 

pursuant to current FHWA regulations 

and guidance. 

The EIS will be prepared as a tiered 

document, providing a systematic 

approach for advancing potential 

transportation improvements. The 

analyses undertaken during Tier 1 will 

result in identification of the preferred 

corridor alternative that best meets the 

study purpose and need. The FHWA 

intends to issue a single Final Tier 1 EIS 

and Record of Decision (ROD) unless 

FHWA determines statutory criteria or 

practicability considerations precluding 

issuance of a combined document. If the 

combined Final Tier 1 EIS/ROD 

identifies an Action (Build) alternative, 

MDTA will complete a Tier 2 NEPA 

document where the agency will 

evaluate site-specific, project level 

impacts and required mitigation 

commitments. The scope of future 

environmental studies will be 

commensurate with the proposed action 

and potential environmental 

consequences. 

FHWA and MDTA will undertake a 

scoping process for the Chesapeake Bay 

Crossing Study that will allow the 

public and interested agencies to 

comment on the scope of the Tier 1 EIS. 

This public outreach effort will educate 

and engage stakeholders, and solicit 

stakeholder input. FHWA and MDTA 

will invite all interested individuals, 

organizations, and public agencies to 

comment on the scope of the Tier 1 EIS, 

including the purpose and need, 

corridor alternatives to be studied, 

impacts to be evaluated, and evaluation 

methods to be used. 

FHWA and MDTA will develop 

preliminary public outreach materials 

(such as fact sheets, brochures, maps or 

other materials) to support the scoping 

process. A public scoping presentation 

in webinar format will be held in 

November 2017. The meeting will be 

held online and available for viewing at 

the study Web site 

(www.baycrossingstudy.com). MDTA 

will also provide local viewing of the 

presentation at multiple locations. 

Presentation times and locations will be 

announced on the project Web site, in 

newspaper advertisements, and by other 

media. 

Initial scoping will provide an 

opportunity for public input on issues 

relevant to the Tier 1 EIS. More 

information on public outreach 

activities, including future public open 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
47292 Federal Register / Vol. 82, No. 195 / Wednesday, October 11, 2017 / Notices 

houses, will be available in a project 

coordination plan on the study Web 

site. All public meetings related to the 

study will be held in locations 

accessible to persons with disabilities. 

Any person who requires special 

assistance, such as a language 

interpreter, should contact the 

Chesapeake Bay Crossing Study: Tier 1 

NEPA Team at (410) 537–5650 or via 

email at info@baycrossingstudy.com at 

least 48 hours before the open house or 

meeting. 

Letters inviting agencies to be 

cooperating or participating in the 

environmental review process are being 

sent to those agencies that have 

jurisdiction or may have an interest in 

the Chesapeake Bay Crossing Study: 

Tier 1 NEPA. FHWA and MDTA will 

notify cooperating and participating 

agencies of a separate agency scoping 

meeting to be held October 25, 2017, in 

Annapolis, Maryland. 

Written comments or questions on the 

scope of the Tier 1 EIS should be mailed 

to the Chesapeake Bay Crossing Study: 

Tier 1 NEPA, c/o Ms. Melissa Williams, 

Director, Division of Planning & 

Program Development, Maryland 

Transportation Authority, 2310 

Broening Highway, Baltimore, MD 

21224; sent via email to mwilliams9@

mdta.state.md.us; or submitted on the 

study Web site 

(www.baycrossingstudy.com). 

(Catalog of Federal Domestic Assistance 

Program Number 20.205, Highway Research, 

Planning and Construction. The regulations 

implementing Executive Order 12372 

regarding intergovernmental consultation on 

Federal programs and activities apply to this 

program.) 

Issued on: October 2, 2017. 

Gregory Murrill, 

Division Administrator, Federal Highway 

Administration, Baltimore, Maryland. 

[FR Doc. 2017–21916 Filed 10–10–17; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF TRANSPORTATION 

Federal Motor Carrier Safety 

Administration 

[Docket No. FMCSA–2009–0155; FMCSA– 

2011–0125; FMCSA–2011–0144; FMCSA– 

2011–0145; FMCSA–2013–0019; FMCSA– 

2013–0181; FMCSA–2015–0062; FMCSA– 

2015–0063] 

Qualification of Drivers; Exemption 

Applications; Diabetes 

AGENCY: Federal Motor Carrier Safety 

Administration (FMCSA), DOT. 

ACTION: Notice of final disposition. 

SUMMARY: FMCSA announces its 

decision to renew exemptions for 127 

individuals from its prohibition in the 

Federal Motor Carrier Safety 

Regulations (FMCSRs) against persons 

with insulin-treated diabetes mellitus 

(ITDM) from operating commercial 

motor vehicles (CMVs) in interstate 

commerce. The exemptions enable these 

individuals with ITDM to continue to 

operate CMVs in interstate commerce. 

DATES: Each group of renewed 

exemptions were applicable on the 

dates stated in the discussions below 

and will expire on the dates stated in 

the discussions below. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Christine A. Hydock, Chief, Medical 

Programs Division, 202–366–4001, 

fmcsamedical@dot.gov, FMCSA, 

Department of Transportation, 1200 

New Jersey Avenue SE., Room W64– 

224, Washington, DC 20590–0001. 

Office hours are from 8:30 a.m. to 5:30 

p.m., e.t., Monday through Friday, 

except Federal holidays. If you have 

questions regarding viewing or 

submitting material to the docket, 

contact Docket Services, telephone (202) 

366–9826. 

SUPPLEMENTARY INFORMATION: 

I. Electronic Access 

You may see all the comments online 

through the Federal Document 

Management System (FDMS) at: http:// 

www.regulations.gov. 

Docket: For access to the docket to 

read background documents or 

comments, go to http//

www.regulations.gov and/or Room 

W12–140 on the ground level of the 

West Building, 1200 New Jersey Avenue 

SE., Washington, DC, between 9 a.m. 

and 5 p.m., e.t., Monday through Friday, 

except Federal holidays. 

Privacy Act: In accordance with 5 

U.S.C. 553(c), DOT solicits comments 

from the public to better inform its 

rulemaking process. DOT posts these 

comments, without edit, including any 

personal information the commenter 

provides, to http://www.regulations.gov, 

as described in the system of records 

notice (DOT/ALL–14 FDMS), which can 

be reviewed at http://www.dot.gov/ 

privacy. 

II. Background 

On July 27, 2017, FMCSA published 

a notice announcing its decision to 

renew exemptions for 127 individuals 

from the insulin-treated diabetes 

mellitus prohibition in 49 CFR 

391.41(b)(3) to operate a CMV in 

interstate commerce and requested 

comments from the public (82 FR 

35029). The public comment period 

ended on August 28, 2017, and one 

comment was received. 

As stated in the previous notice, 

FMCSA has evaluated the eligibility of 

these applicants and determined that 

renewing these exemptions would 

achieve a level of safety equivalent to or 

greater than the level that would be 

achieved by complying with the current 

regulation 49 CFR 391.41(b)(3). 

The physical qualification standard 

for drivers regarding diabetes found in 

49 CFR 391.41(b)(3) states that a person 

is physically qualified to drive a CMV 

if that person: 

Has no established medical history or 

clinical diagnosis of diabetes mellitus 

currently requiring insulin for control. 

III. Discussion of Comments 

FMCSA received one comment in this 

preceding. An anonymous commenter 

stated they believe the rule preventing 

drivers with ITDM operating CMVs in 

interstate commerce should be removed 

and the medical examiners should 

determine whether a driver is fit to 

operate a CMV in interstate commerce. 

On May 4, 2015, FMCSA published a 

Notice of Proposed Rulemaking (NPRM) 

(80 FR 25260) proposing changes to the 

Diabetes standard and requesting 

comments from the public. FMCSA is 

currently evaluating comments received 

and drafting a Final Rule. Information 

related to this action can be found in the 

Docket at FMCSA–2005–23151. 

IV. Conclusion 

Based upon its evaluation of the 127 

renewal exemption applications and 

comments received, FMCSA announces 

its’ decision to exempt the following 

drivers from the rule prohibiting drivers 

with ITDM from driving CMVs in 

interstate commerce in 49 CFR 

391.64(3): 

As of August 1, 2017, and in 

accordance with 49 U.S.C. 31136(e) and 

31315, the following 35 individuals 

have satisfied the renewal conditions for 

obtaining an exemption from the rule 

prohibiting drivers with ITDM from 

driving CMVs in interstate commerce 

(80 FR 37719; 80 FR 59223): 

Adele M. Aasen (ND) 

Kyle E. Beine (WI) 

Joseph M. Blackwell (GA) 

Joseph G. Blastick (SD) 

Gary W. Boninsegna (OH) 

Billy J. Bronson (OR) 

Michael L. Campbell (NC) 

Steven C. Cornell (PA) 

Josiah L. Crestik (MN) 

Richard L. Cunningham (NE) 

Thomas M. Delasko (FL) 

William T. Eason (NC) 

Douglas J. Garrison (IA) 

Daniel W. Gregory (NC) 

Barry L. Grimes, Sr. (MD) 

Dennis J. Grimm (DE) 


asabaliauskas on DSKBBXCHB2PROD with NOTICES